Ling Mei

Dr. Ling Mei

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2025 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
QDQihang Ding
Qihang Ding
YXYuxin Xie
Yuxin Xie
KXKexin Xiong
Kexin Xiong
HJHaolan Jia
Haolan Jia
LCLin Chen
Lin Chen
Ben Zhong TangBen Zhong Tang
Ben Zhong Tang

30 September 2009 in Immunogenetics
Verified
Journal Article
Open access
PDF file
JHJill A. Hollenbach
Jill A. Hollenbach
MLMartha B. Ladner
Martha B. Ladner
KSKoy Saeteurn
Koy Saeteurn
KTKent D Taylor
Kent D Taylor
LMLing Mei
Ling Mei
ETElizabeth A. Trachtenberg
Elizabeth A. Trachtenberg
In the present study, we investigated the relationship between the KIR loci and the genes encoding their HLA ligands and genetic susceptibility to Crohn’s disease (CD). Analyses of the interactions between KIR3DL1, KIR2DL1, KIR2DL2, and KIR2DL3 with their respective HLA ligands indicate that there is a protective effect for KIR2DL2 in the absence of its HLA ligand C1. Given that KIR2DL2 and KIR2DL3 segregate as alleles, we compared their genotypic distributions to expectations under Hardy–Weinberg Equilibrium (HWE) with regard to the HLA ligand C1 status. While all the genotypic distributions conform to expectations under HWE in controls, in C2 ligand homozygous cases there is significant deviation from HWE, with a reduction of KIR2DL2, KIR2DL3 heterozygotes. KIR2DL2, KIR2DL3 heterozygosity is the only genotypic combination that confers protection from CD. In addition to the protective effect (OR = 0.44, CI = 0.22–0.87; p = 0.018) observed in C2 ligand homozygotes, the KIR2DL2, KIR2DL3 genotype is predisposing (OR = 1.34, CI = 1.03–4.53; p = 0.031) in the presence of C1 ligand. A test for trend of HLA class I C ligand group genotypes with KIR2DL2, KIR2DL3 heterozygosity in cases and controls indicates that C1, C2 ligand group heterozygotes have an intermediate effect on predisposition. These results show for the first time that disease susceptibility may be related to heterozygosity at a specific KIR locus, and that HLA ligand genotype influences the relative effect of the KIR genotype.

12 June 2025 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
QDQihang Ding
Qihang Ding
HLHaowei Liu
Haowei Liu
LYLishan Yan
Lishan Yan
LCLiang Chen
Liang Chen
Yu ChenYu Chen
Yu Chen
LMLing Mei
Ling Mei
Melanoma is characterized by rapid growth and high invasiveness, resulting in an exceptionally high malignancy and a significant propensity for metastasis. Current therapeutic modalities, such as chemotherapy and radiotherapy, exhibit limited efficacy due to severe side effects and immunosuppressive effects. Consequently, the development of precise and effective integrated therapeutic strategies is of paramount importance. Here, we report a multifunctional and multienzyme active nanosystem (FeCP@PDA‐GOx) that synergistically integrates starvation therapy, chemodynamic therapy, mild photothermal therapy (mPTT), and immunotherapy to achieve multidimensional therapeutic effects. This nanoplatform harnesses the enzymatic activities of glucose oxidase, peroxidase, oxidase, and catalase to enhance tumor microenvironment modulation and drug delivery efficiency, ultimately inducing ferroptosis in tumor cells. The system also establishes a positive feedback loop to further amplify its catalytic performance. Additionally, it effectively suppresses the expression of heat shock proteins in tumor cells, thereby augmenting the therapeutic efficacy of mPTT. Moreover, the system activates robust immune responses, suppressing lung metastasis and eliciting systemic antitumor effects to inhibit the growth of distal tumors. Experimental results demonstrate that this multifunctional nanoplatform exhibits exceptional therapeutic efficacy and safety in melanoma treatment, laying a solid foundation for the advancement of personalized medicine and intelligent therapeutic strategies.

21 November 2024 in Materials Today Bio
Verified
Journal Article
Open access
LMLing Mei
Ling Mei
YZYifan Zhang
Yifan Zhang
KWKaixi Wang
Kaixi Wang
SCSijing Chen
Sijing Chen
TSTao Song
Tao Song
In the face of the increasing resistance of microorganisms to traditional antibiotics, the development of innovative treatment methods is becoming increasingly urgent. Nanophototherapy technology can precisely target the infected area and achieve synergistic antibacterial effects in multiple modes. This phototherapy method has shown significant efficacy in treating diseases caused by drug-resistant bacteria, especially in the elimination of biofilms, where it has demonstrated strong dissolution capabilities. PTT utilizes photothermal agents to convert near-infrared light into heat, effectively killing bacteria and promoting tissue regeneration. Similarly, PDT utilizes photosensitizers, which produce reactive oxygen species (ROS) when activated by light, destroying the structure and function of bacterial cells. This review summarizes photothermal agents and photosensitizers used for antibacterial purposes. In conducting our literature review, we employed a systematic approach to ensure a comprehensive and representative selection of studies. Additionally, this article explores the potential of phototherapy in regulating wound microenvironments, promoting wound healing, and activating the immune system. Nanophototherapeutic materials show great potential for application in antibacterial treatment and are expected to provide innovative solutions for drug-resistant bacterial infections that traditional antibiotics are struggling to address.

17 January 2017 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
LMLing Mei
Ling Mei
YLYayuan Liu
Yayuan Liu
CXChunyu Xia
Chunyu Xia
YZYubei Zhou
Yubei Zhou
ZZZhirong Zhang
Zhirong Zhang
Xingli CunXingli Cun
Xingli Cun

26 July 2024 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
HDHongbo Dong
Hongbo Dong
YYYuanwei You
Yuanwei You
NWNa Wang
Na Wang
MWMengqi Wang
Mengqi Wang
TSTao Song
Tao Song
LMLing Mei
Ling Mei